Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single vs. Multiple Fraction Non-Inferiority Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligo-metastases/Progression: SIMPLIFY-SABR-COMET

NCT05784428 is registered in ClinicalTrials.gov with Robert Olson as lead sponsor.

NCT NCT05784428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05784428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single vs. Multiple Fraction Non-Inferiority Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligo-metastases/Progression: SIMPLIFY-SABR-COMET
Lead sponsor
Robert Olson
Phase
Not applicable
Overall status
Recruiting
Start date
April 16, 2025
Completion date
May 30, 2035
Enrollment
598 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic disease, oligoprogression, quality of life, toxicity due to radiotherapy